EFA joins a new EU4Health project: LungHealth4Life (LH4L)
EFA is thrilled to join the LungHealth4Life (LH4L) project aiming to boost lung health through early intervention in schools across Europe. Leading the...
EFA Project: COPD Standards of Care – Raising the bar!
Shaping the Future of COPD Care: From Minimum to Optimal
A Call to Action to Stop Ignoring a Silent Disease Impacting Millions
Imagine coughing...
EFA and our Belgian members - Astma en Allergiekoepel, discuss Indoor Air Quality plans with the Belgian Ministry of Health
On 27 June, EFA and our Belgian member association - Astma en Allergiekoepel (AAK) had a joint meeting with the Belgian Federal Ministry of Health's Indoor...
EFA co-signs letter to Von der Leyen calling for Vice-President for Health, Wellbeing and Social Rights
In July, together with our partners from the EU4Health Civil Society Alliance (CSA), EFA co-signed a letter addressed to the President of the European...
Annual Report 2023: an overview of the patients agenda for allergy and airways diseases
Our Annual Report 2023 reflects a year of dedication and progress in improving the lives of respiratory patients in Europe. EFA has launched a new programmatic...
EFA responds to the HTA consultation on the cooperation with the EMA
EFA has actively engaged in the EU Health Technology Assessment (HTA) consultation, emphasising the importance of collaboration between HTA bodies and...
EFA calls for strong patient involvement in EU Health Technology Assessments
EFA has responded to another proposal for legislation completing the EU Health Technology Assessment Regulation (HTAR) that will determine how individual...
EFA attends the EU Partnership for the Assessment of Risks from Chemicals (PARC) forum
EFA participated in the 3rd Stakeholder Forum meeting of the Partnership for the Assessment of Risk from Chemicals (PARC), the EU-funded project advancing...
EFA is offering EUPATI Patient Expert Training Scholarships to Members – deadline extended!
Since 2022, EFA has been supporting its community of members with scholarships to participate in the European Patients’ Academy on Therapeutic Innovation’s...
Salbutamol is in shortage in Europe
On 6 June, the European Medicines Agency (EMA) added salbutamol, a life-saving medicine for chronic respiratory disease and especially for children...
EFA contributed to the EMA review of the first critical medicines list of the EU
EFA recently contributed to the European Medicines Agency (EMA) targeted stakeholder consultation which reviewed the first Union list of critical medicines...
EFA contributes to a consultation on strategic priorities of the EU health programme for 2025
Early June, EFA responded to the stakeholders’ consultation around the strategic priorities of the 2025 Annual Work Programme of the EU health programme...
Asthma inhalers and climate labelling for patients: EFA informs the new F-Gases labelling rules for MDIs
If you have asthma or COPD, you might be using an inhaler to help you manage your disease. Some inhalers use a gas, known as propellants, which delivers...
EFA calls on the WHO to include specific priorities for allergy and lung health in the future NCD plan
On 17 June, EFA submitted a response to a first stage consultation to update the WHO on its Global Action Plan (GAP) 2013–2020 for the prevention and...
European Lung Health Group presents the #KeepBreathing campaign to European Commission’s DG SANTE and DG CONNECT in Luxembourg
On 13 June, representatives from EFA and the European Respiratory Society (ERS), travelled to Luxembourg on behalf of the European Lung Health Group (ELHG)...
EFA attends EU HTA Stakeholder Network meeting in Brussels
The EU HTA Stakeholder Network meeting focused on the involvement of patients in the Health Technology Assessment (HTA) process. Together with the European...
EFA attends EAACI Congress 2024
EFA representatives Celine Demoulin and Susanna Palkonen attended the EAACI Congress 2024 in Valencia. This year’s theme revolved around revolutionising...
EFA brings the patient perspective into the EMA Guideline for immunotherapy and diagnosis of less common allergies
At the end of May, EFA submitted our allergy community response to a key consultation for the allergy patient community: a Guideline on the development...
Join patients on World Atopic Eczema Day 2024 – toolkit now available!
This year’s #AtopicEczemaUnfiltered campaign will bring to the forefront the real experiences of people living with Atopic Eczema and shed light on the...
EFA joins the IDEAL Cluster Annual General Meeting 2024 on indoor air quality and health
As a partner of the EU Horizon research project 'SynAir-G' and a member of the 'IDEAL research Cluster', EFA joined the IDEAL Annual General Meeting 2024...